Patents Assigned to Torrent Pharmaceuticals Ltd.
  • Patent number: 9629818
    Abstract: The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for parenteral administration and its use in the treatment of pain.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: April 25, 2017
    Assignee: TORRENT PHARMACEUTICALS LTD.
    Inventors: Sunil Sadanand Nadkarni, Jaya Abraham, Kapil Khatri
  • Publication number: 20150290146
    Abstract: The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for parenteral administration and its use in the treatment of pain.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 15, 2015
    Applicant: TORRENT PHARMACEUTICALS LTD
    Inventors: Sunil Sadanand Nadkarni, Jaya Abraham, Kapil Khatri
  • Publication number: 20140170209
    Abstract: The present invention relates to a pharmaceutical composition of tapentadol for nasal administration. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for nasal administration and its use in the treatment of pain.
    Type: Application
    Filed: July 19, 2012
    Publication date: June 19, 2014
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventors: Sunil Sadanand Nadkarni, Jaya Abraham, Kapil Khatri, Vipul Mittal
  • Patent number: 8378118
    Abstract: The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: February 19, 2013
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventors: Laxmikant Chhipa, Shitalkumar Pukharaj Zambad, Ramesh Gupta, Davinder Tuli, Ashok Kasundra, Siralee Munshi, M. Amir Siddiqui, Subrat Kumar Bhattamisra, C. Dutt, Vijay Chauthaiwale
  • Publication number: 20120202816
    Abstract: The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.
    Type: Application
    Filed: January 10, 2012
    Publication date: August 9, 2012
    Applicant: Torrent Pharmaceuticals, Ltd.
    Inventors: Laxmikant Chhipa, Shitalkumar Pukharaj Zambad, Ramesh Gupta, Davinder Tuli, Ashok Kasundra, Siralee Munshi, M. Amir Siddiqui, Subrat Kumar Bhattamisra, C. Dutt, Vijay Chauthaiwale
  • Patent number: 8143424
    Abstract: A novel thyroid like compounds of formula (I), wherein R1, R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition and use thereof. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions including obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: March 27, 2012
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventors: Laxmikant Chhipa, Shitalkumar Pukharaj Zambad, Ramesh Gupta, Davinder Tuli, Ashok Kasundra, Siralee Munshi, M. Amir Siddiqui, Subrat Kumar Bhattamisra, Chaitanya Dutt, Vijay Chauthaiwale
  • Patent number: 7939102
    Abstract: Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered once or more times a day.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: May 10, 2011
    Assignees: Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Torrent Research Center
    Inventors: Sunil Sadanand Nadkarni, Navin Vaya
  • Publication number: 20110027361
    Abstract: The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same.
    Type: Application
    Filed: February 3, 2009
    Publication date: February 3, 2011
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventors: Ganesan Murugesan, Jaya Abraham, Vinodkumar Gupta, Bhavesh Shah
  • Publication number: 20100168110
    Abstract: The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.
    Type: Application
    Filed: June 2, 2008
    Publication date: July 1, 2010
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventors: Laxmikant Chhipa, Shitalkumar Zambad, Ramesh Gupta, Davinder Tuli, Ashok Kasundra, Siralee Munshi, M. Amir Siddiqui, Subrat Kumar Bhattamisra, C. Dutt, Vijay Chauthaiwale
  • Publication number: 20080226711
    Abstract: The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat.
    Type: Application
    Filed: March 11, 2008
    Publication date: September 18, 2008
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventors: Sheth Rakesh K., Setty Umesh, Patel Hasmukh M.
  • Patent number: 7223777
    Abstract: The invention discloses a new clause of a five membered heterocylic ring compounds of general formula I and its pharmaceutically or cosmetically acceptable salts, wherein R1, R2, R3, R4, R5, A, B, X and Y are as defined in the specification. The invention also discloses a process for preparation of these compound and their therapeutic and cosmetic applications particularly in the management of aging related and diabetic vascular complications. The compounds in question act by triple action of an AGE (Advanced Glycation Endproducts) breaker, AGE inhibitor and free radical scavenger which make them most suitable in different therapeutic and cosmetic applications. The invention also discloses pharmaceuticals and cosmetic compositions comprising these compounds and method of treatment of diseases caused by accumulation of AGE and/or free radicals in the body cells.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: May 29, 2007
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventor: Alangudi Sankaranarayanan
  • Patent number: 7138416
    Abstract: The invention discloses a novel series of compound represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, and solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood glucose levels in diabetics, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals in mammals.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: November 21, 2006
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventor: Alangudi Sankaranarayanan
  • Publication number: 20060167113
    Abstract: The invention discloses a process for preparation of sertraline salts particularly sertraline hydrochloride Form V by dissolving or suspending sertraline mandelate in a solvent, reducing the pH of the solution or the suspension and isolating salt of sertraline The invention also provides for a pharmaceutical composition comprising said sertraline salt as active ingredient
    Type: Application
    Filed: November 3, 2003
    Publication date: July 27, 2006
    Applicant: Torrent Pharmaceuticals Ltd.
    Inventor: Sunil Nadkarni
  • Publication number: 20040106802
    Abstract: The invention discloses a novel series of compound represented by general formula (I), 1
    Type: Application
    Filed: November 26, 2003
    Publication date: June 3, 2004
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan
  • Publication number: 20030225102
    Abstract: The invention discloses a novel series of compound represented by general formula (I), 1
    Type: Application
    Filed: April 8, 2003
    Publication date: December 4, 2003
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan
  • Patent number: 6624178
    Abstract: The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: September 23, 2003
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventor: Alangudi Sankaranarayanan
  • Patent number: 6608094
    Abstract: Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular and neurovascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, inflammatory disorders, immunological disorders, oxidative stress, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. Also disclosed is a method for preparation of the compounds of general formula (I) and pharmaceutical composition containing one or more compounds as defined above as active ingredients. Also disclosed is a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: August 19, 2003
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventor: Alangudi Sankaranarayanan
  • Publication number: 20030092744
    Abstract: The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, 1
    Type: Application
    Filed: August 9, 2002
    Publication date: May 15, 2003
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan
  • Publication number: 20030045554
    Abstract: The invention discloses a new clause of a five membered heterocylic ring compounds of general formula 1 1
    Type: Application
    Filed: April 5, 2002
    Publication date: March 6, 2003
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan
  • Publication number: 20030032660
    Abstract: Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular and neurovascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, inflammatory disorders, immunological disorders, oxidative stress, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, 1
    Type: Application
    Filed: August 28, 2001
    Publication date: February 13, 2003
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan